Having type 2 diabetes doubles your risk for heart disease.
There are two classes of diabetes medications that have been shown to reduce that risk, SGLT2 inhibitors and GLP-1 receptor agonists. It is not known how these classes compare to each other.
What does the study involve?
Our study team will work with your regular health care provider to fit the study medication into your usual diabetes care. Your current diabetes medications may be adjusted.
Visits & Surveys
First visit in-person or by video conference. This will help make sure the medicines are safe and affordable for you. If you agree to participate, you will complete questionnaires, and be assigned your medication.
Follow-up visit or call with study team two months later.
One survey per year by phone and online between the yearly visits.
One in-person or video conference visit per year.
Medications
SGLT2 inhibitors such as Jardiance, Farxiga, Invokana
GLP-1 receptor agonists such as Victoza, Trulicity, Ozempic, Rybelsus
Our study team will send prescriptions to your usual pharmacy. You will pick up the prescriptions as you do your other prescriptions.
Medications and lab tests will be billed to your insurance company. Our study team will help assess your insurance coverage.
Timeline
This study lasts through 2029 because we want to see what the long-term effects of the medications are on important outcomes like heart attack and stroke.
Questions?
Study team contact(s): (833) 879-0139 | PRECIDENTDCCC@BWH.harvard.edu
Advarra Institutional Review Board:
toll free: 877-992-4724 • email: adviser@advarra.com